Results:
Between November 2021 and March 2022, a total of 62 subjects received
Sotrovimab infusion at AUBMC. Patients had a mean age of 59.7 years and
an average Body Mass Index (BMI) of 26.72 Kg/m2. Most
of the patients were males (66.1%), and almost half were smokers
(51.6%).
More than 70% of subjects were vaccinated against COVID-19 (Pfizer
AstraZeneca, Sinopharm, and other various vaccines), and 25 (43.1%) out
of 62 had received two doses of any COVID-19 vaccine. The average
duration of symptoms before hospital presentation was 3.97±4.5 days. The
baseline characteristics are shown in Table 1.
Regarding patient comorbidities, hypertension was the most
common and was present in 56.5% of subjects, followed by hematological
malignancies with a rate of 35.5%. The prevalence rates of all
comorbidities are listed in (Figure1) ,
The subject population was grouped according to the NIH criteria for
prioritizing the use of anti-SARS-CoV-2 therapies [15] and it was
found that 77% of the population belonged to Tier 1, 8.1 % to Tier 2,
and 14.5 % to Tier 3 (Table 2) .
Concerning the ongoing chronic treatment of the subjects, 40.3% of the
62 subjects were on active chemotherapy and 17.7% of them were
currently receiving or previously received rituximab within the past 12
months (Table 3) .
We calculated the primary and the secondary outcomes using SPSS by
adding the patients with the specific outcome to generate the total
number (N) and we divided them by the total number of patients to get
the percentage (%). For the primary outcomes, 39 subjects received the
drug in the ED and did not require hospitalization (62.9%). 23 subjects
(37.1%) were hospitalized: 13 of them required hospitalization due to
COVID- 19 (and received Sotrovimab subsequently), whereas the other 10
patients were already hospitalized when they acquired COVID-19
infection. Thirteen patients (21.0%) experienced clinical deterioration
24 hours after Sotrovimab infusion and only four patients (6.5%) died
due to any cause at 60 days after the infusion. For the secondary
outcomes, six patients (9.7%) out of the total subjects progressed to
critical illness and no adverse events were reported in any of the
subjects (Table-4).
Concerning the appropriateness of Sotrovimab use based on the
institution criteria developed as mentioned above, we found that
Sotrovimab administration was appropriate and in compliance with the
NIH-derived institution criteria in 61 out of the 62 (98.4%) patients.